Healthcare earnings in January
Healthcare companies have been reporting mixed results for the fourth quarter of 2018 and fiscal 2018 in January 2019. Stocks such as Pfizer (PFE), Johnson & Johnson (JNJ), Amgen, Biogen, and Bristol-Myers Squibb (BMY) have managed to surpass both the consensus revenue and adjusted EPS estimate in the fourth quarter. On the other hand, AbbVie (ABBV) and Abbott Laboratories (ABT) missed their consensus revenue estimates in the fourth quarter.
Many of these healthcare companies have cited the impact of the loss of exclusivity (or LOE) for certain key brands, pricing pressures in the US, and unfavorable foreign currency fluctuations as factors that affected their revenue performance.
Healthcare earnings scheduled in February
The first major healthcare company scheduled to announce its fourth-quarter 2018 and fiscal 2018 results in February is Merck (MRK). The company plans to release its earnings results before the market opens on February 1. Alexion Pharmaceuticals and Gilead Sciences (GILD) are set to announce results on February 4, while Becton Dickinson, Array Biopharma, Haemonetics, and Bio-Techne plan to announce on February 5. Eli Lilly (LLY), Regeneron Pharmaceuticals, and Humana are scheduled to announce their earnings results on February 5, while Boston Scientific is slated to announce results on February 6.
Wall Street analysts expect Merck, Eli Lilly, Gilead Sciences, and Regeneron Pharmaceuticals to report YoY revenue change of 5.39%, 6.77%, -16.43%, and 10.77%, respectively, in fiscal 2018. Merck, Eli Lilly, Gilead Sciences, and Regeneron Pharmaceuticals are expected to report YoY adjusted diluted EPS change of 8.79%, 30.15%, -21.68%, and 32.47%, respectively, for fiscal 2018.